Skip to main content

Advertisement

Fig. 1 | Molecular Cancer

Fig. 1

From: Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy

Fig. 1

Progression of CML from chronic phase (CP) to blastic phase (BP). Biologically, the transition is associated with the accumulation of additional hits in BCR-ABL1 itself (TKI-resistant kinase domain mutations) or in other genes/chromosomes. In the latter case, the degree of oncogenic addiction decreases, and inhibiting BCR-ABL1 alone may not be sufficient any more. This translates into an increase of drug resistance and in poor response to current therapies. ‘X’, ‘Y’ and ‘Z’ represent additional altered molecules other than BCR-ABL1

Back to article page